PROGYNY INC

PGNYNASDAQ

🏆 #1507 by market capEarnings Nov 4US Equity

$26.57▼ $1.22 (−4.60%)

Live

1h—

24h▼ 4.6%

7d▼ 15.2%

14d▼ 15.3%

30d▼ 16.9%

1y▲ 22.1%

🏦Market Cap

$2.08B

Small Cap

📈Revenue Growth (YoY)

+5.5%

Slowing

📊Gross Margin

24.6%

Moderate

💵FCF Margin

13.6%

Healthy

⚖️P/S Ratio

1.7x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $26.41 – $26.80
52-Week Range: $16.10 – $33.07
Volume: $2.59B
Avg Volume: $3.22B
Shares Outstanding: 78.3M
Next Earnings: Sep 25, 2026

Fundamentals Snapshot

Annual Revenue: $1.29B
Last Q Revenue: $351M
P/E Ratio: 27.9
P/S Ratio: 1.7x
EPS (TTM): $0.92
Dividend Yield: —

Why Investors Own PGNY

✓High-growth profile — revenue up -7.4% YoY with expanding US Equity exposure.
✓Healthy economics — 76% gross margin and 27% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$1.29B▼ −11.2% YoY

Gross Margin (TTM)

75.7%▲ +3.2% YoY

Operating Income (TTM)

$438M▼ −11.2% YoY

Free Cash Flow (TTM)

$352M▼ −11.2% YoY

About PROGYNY INC

Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.

🦦